
Astellas GLOWing as Claudin drug aces gastric cancer trial
Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.
Newsletters and Deep Dive digital magazine
Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.
New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.
IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.
LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.
Editor's Picks
Newsletters and Deep Dive
digital magazine